Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ET (Essential Thrombocythemia)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05025488
What this trial is testing

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Who this might be right for
MyelofibrosisEssential ThrombocythemiaMPN
Marina Kremyanskaya 10
Large-scale testing (Phase 3)Ended earlyNCT02962388
What this trial is testing

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Who this might be right for
Essential Thrombocythemia
French Innovative Leukemia Organisation 13
Not applicableStudy completedNCT00433862
What this trial is testing

Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders

Who this might be right for
Polycythemia VeraEssential ThrombocytosisIdiopathic Myelofibrosis+2 more
National Institutes of Health Clinical Center (CC) 8
Large-scale testing (Phase 3)Study completedNCT03952039
What this trial is testing

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia VeraMyelofibrosis
Celgene 202
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574
What this trial is testing

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more
Chengdu Zenitar Biomedical Technology Co., Ltd 105
Early research (Phase 1)UnknownNCT05279001
What this trial is testing

A Safety and Tolerability Study of Jaktinib

Who this might be right for
Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 26
Not applicableStudy completedNCT01352585
What this trial is testing

Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®

Who this might be right for
Essential Thrombocythemia (ET)
Shire 47
Large-scale testing (Phase 3)Active Not RecruitingNCT04285086
What this trial is testing

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Who this might be right for
Essential Thrombocythemia
PharmaEssentia 174
Testing effectiveness (Phase 2)Active Not RecruitingNCT05482971
What this trial is testing

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Who this might be right for
Essential Thrombocythemia
PharmaEssentia 91
Testing effectiveness (Phase 2)Ended earlyNCT01668173
What this trial is testing

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Who this might be right for
Myeloproliferative Neoplasms
Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT02098161
What this trial is testing

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Who this might be right for
Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary MyelofibrosisSecondary Myelofibrosis
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT00606307
What this trial is testing

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Who this might be right for
Myeloproliferative Diseases
Italfarmaco 29
Large-scale testing (Phase 3)Looking for participantsNCT04655092
What this trial is testing

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Who this might be right for
Polycythemia Vera (PV)
PharmaEssentia Japan K.K. 67
Very early researchEnded earlyNCT03972943
What this trial is testing

CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia

Who this might be right for
CALR Gene MutationEssential ThrombocythemiaJAK2 Gene Mutation+3 more
University of Utah 8
Testing effectiveness (Phase 2)Study completedNCT01200498
What this trial is testing

Study of SB939 in Subjects With Myelofibrosis

Who this might be right for
Myeloproliferative Disorders
M.D. Anderson Cancer Center 23
Not applicableStudy completedNCT01970930
What this trial is testing

Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients

Who this might be right for
Polycythemia VeraEssential Thrombocythemia
Icahn School of Medicine at Mount Sinai 131
Testing effectiveness (Phase 2)Study completedNCT01787552
What this trial is testing

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Who this might be right for
Primary MyelofibrosisThrombocytosisEssential Thrombocythemia+7 more
Novartis Pharmaceuticals 50
Testing effectiveness (Phase 2)Study completedNCT00509899
What this trial is testing

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Who this might be right for
MyelofibrosisPolycythemia VeraThrombocytosis
Incyte Corporation 154
Testing effectiveness (Phase 2)Study completedNCT02515630
What this trial is testing

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV) MyelofibrosisPostessential Thrombocythemia (Post-ET) Myelofibrosis
Sierra Oncology LLC - a GSK company 41
Testing effectiveness (Phase 2)UnknownNCT04485260
What this trial is testing

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
Myelofibrosis
Kartos Therapeutics, Inc. 36
Next Page